US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

249.65

-16.1400-6.07%

Pre-market: 256.006.35+2.54%07:13 EDT

Volume:444.68K

Turnover:115.14M

Market Cap:567.83M

PE:- -

High:271.79

Open:261.76

Low:248.93

Close:265.79

52wk High:341.93

52wk Low:95.98

Shares:2.27M

Float Shares:2.27M

Volume Ratio:1.37

T/O Rate:19.55%

Dividend:0.90

Dividend Rate:0.36%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)

Is Ping An Healthcare And Technology (SEHK:1833) Undervalued After Its GlobalCare Launch?

Simply Wall St.

LIVE Markets-TD Cowen Says AI Promises Hospitals a Margin Cure

Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38

LIVE Markets-Cooler than Expected PCE Adds Some Steam to US Stock Futures

Health Care Select Sector SPDR: Pivot points

Abbott announces U.S. commercial launch of SimpleScreen CRC

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

CeriBell Receives FDA Clearance for Platform Software Update

MT Newswires Live

Tiziana Life Sciences Seeks FDA Orphan Status for Intranasal Foralumab in Multiple System Atrophy

Ceribell receives FDA 510k clearance of quantitative EEG trending, analysis

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Aldeyra Therapeutics: Neutral Rating Maintained Amid FDA Uncertainty; $2 Price Target Reaffirmed

Roche’s Genentech announces FDA approves NDA for fenebrutinib

Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)

Health Care Roundup: Market Talk

Yamashita Health Care Sees FY Net Y553.00m

HUTCHMED Shares Rise Over 3% After Announcing FDA Submission for Orpathys and Tagrisso Combination Therapy

IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/LABU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":249.65,"timestamp":1790884800000,"preClose":265.79,"halted":0,"volume":444675,"hourTrading":{"tag":"盘前","latestPrice":256,"preClose":249.65,"latestTime":"07:13 EDT","volume":1035,"amount":263401.3521,"timestamp":1790939580205,"change":6.35,"changeRate":0.025436,"amplitude":0.014861},"delay":0,"changeRate":-0.060724632228451085,"floatShares":2274486,"shares":2274486,"eps":0,"marketStatus":"Pre-Mkt","change":-16.14,"latestTime":"10-02 07:14:59 EDT","open":261.76,"high":271.79,"low":248.93,"amount":115144402.4115,"amplitude":0.086008,"askPrice":260.81,"askSize":100,"bidPrice":254,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":249.65,"sharesOutstanding":3074486,"nav":265.086,"aum":616188302.35,"dividendRate":0.00362,"bidAskSpread":0.003421,"preHourTrading":{"tag":"盘前","latestPrice":256,"preClose":249.65,"latestTime":"07:13 EDT","volume":1035,"amount":263401.3521,"timestamp":1790939580205,"change":6.35,"changeRate":0.025436,"amplitude":0.014861},"postHourTrading":{"tag":"盘后","latestPrice":251.75,"preClose":249.65,"latestTime":"19:59 EDT","volume":7054,"amount":1775509.5491,"timestamp":1790899181648,"change":2.1,"changeRate":0.008412,"amplitude":0.011416},"volumeRatio":1.3688031629226816,"impliedVol":0.9424,"impliedVolPercentile":0.608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2274486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.3688031629226816,"shares":2274486,"dividePrice":0.9037,"high":271.79,"amplitude":0.086008,"preClose":265.79,"low":248.93,"week52Low":95.98,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":249.65,"committee":0.333333,"eps":0,"divideRate":0.00362,"volume":444675,"delay":0,"ttmEps":0,"open":261.76,"prevYearClose":159.39,"prevWeekClose":252.47,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":257.32,"twentyDayClose":311.81,"sixtyDayClose":317.19},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671851997","title":"Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671851997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671851997?lang=en_us&edition=fundamental","pubTime":"2026-09-30 23:20","pubTimestamp":1790781616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kailera-therapeutics-inc-klra-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kailera-therapeutics-inc-klra-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","HCSG","LU0029874061.USD","BK4581","IMNM","OZEM","XBI","BK4585","KLRA","LU0128526141.USD","XLV","BK4563","BK4137","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672873841","title":"Is Ping An Healthcare And Technology (SEHK:1833) Undervalued After Its GlobalCare Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672873841","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672873841?lang=en_us&edition=fundamental","pubTime":"2026-09-30 22:24","pubTimestamp":1790778257,"startTime":"0","endTime":"0","summary":"Ping An Healthcare and Technology (SEHK:1833) has put its new Ping An GlobalCare platform in the spotlight by launching a trial in Shenzhen that combines AI-driven real-time medical translation with a fully coordinated online and offline care journey.\nAgainst this product launch, Ping An Healthcare and Technology’s recent share price return has been mixed, with a 7 day gain of 4.02% but a 90 day decline of 10.25% and a year to date fall of 56.48% at a HK$6.345 close. Over a longer horizon,...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/5021000-choice2-card/1789013271957","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/5021000-choice2-card/1789013271957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-1833/ping-an-healthcare-and-technology-shares/news/is-ping-an-healthcare-and-technology-sehk1833-undervalued-af","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-1833/ping-an-healthcare-and-technology-shares/news/is-ping-an-healthcare-and-technology-sehk1833-undervalued-af","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01833","LABU","XLV","XBI","HCSG","BK1247","BK1571","BK1515","BK1617","BK4588","BK1219","LU0128526141.USD","LU0029874061.USD","BK1615","BK4581","BK4137","BK4585","DCF","BK1142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671207594","title":"LIVE Markets-TD Cowen Says AI Promises Hospitals a Margin Cure","url":"https://stock-news.laohu8.com/highlight/detail?id=2671207594","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671207594?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:18","pubTimestamp":1790774293,"startTime":"0","endTime":"0","summary":"CLICK HEREWHAT TO THINK ABOUT IN Q4CLICK HERESTOCKS POISED FOR NEXT LEG HIGHER... IF OIL DROPSCLICK HERESTOXX SET FOR MONTHLY FALL, BUT A STEADY QUARTERCLICK HEREBEFORE THE BELL: SET TO END THE MONTH ON A HIGH NOTECLICK HEREA CRUEL QUARTER FOR BONDSCLICK HERE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL6N45M0UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B775SV38.USD","IE00B3S45H60.SGD","LU0211327993.USD","LU0882574055.USD","LU0980610538.SGD","THC","IHF","LU0130103400.USD","LU0114720955.EUR","LU1201861249.SGD","LU0868494617.USD","LU0211328371.USD","LU1201861165.SGD","LU1084165304.USD","LU0187121727.USD","LU1150488135.SGD","LU0648000940.SGD","XLV","LU1150488218.USD","BK4585","LU0130102774.USD","LU0310799852.SGD","LU1261432733.SGD","LU0708994859.HKD","LU1267930490.SGD","UHS","SG9999014039.USD","BK4581","BK4588","SG9999014005.SGD","XBI","LU1489326972.SGD","LU0203347892.USD","LU0878866978.SGD","LU0068578508.USD","LU0985489474.SGD","LU1267930573.SGD","BK4185","HCA","LU0029864427.USD","LU1119994496.HKD","LU0433182093.SGD","LU2244417387.USD","SG9999014021.USD","LABU","LU0203345920.USD","LU0128525929.USD","BK4504","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671207668","title":"Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2671207668","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671207668?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:15","pubTimestamp":1790774145,"startTime":"0","endTime":"0","summary":"Pharming Group, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Whitney Ijem from Canaccord Genuity mainta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pharming-group-buy-rating-maintained-and-strategy-intact-despite-surprise-ceo-departure-price-target-reaffirmed-at-38-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pharming-group-buy-rating-maintained-and-strategy-intact-despite-surprise-ceo-departure-price-target-reaffirmed-at-38-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XBI","BK4585","BK4588","BK4581","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671202023","title":"LIVE Markets-Cooler than Expected PCE Adds Some Steam to US Stock Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2671202023","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671202023?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:09","pubTimestamp":1790773775,"startTime":"0","endTime":"0","summary":"CLICK HEREWHAT TO THINK ABOUT IN Q4CLICK HERESTOCKS POISED FOR NEXT LEG HIGHER... IF OIL DROPSCLICK HERESTOXX SET FOR MONTHLY FALL, BUT A STEADY QUARTERCLICK HEREBEFORE THE BELL: SET TO END THE MONTH ON A HIGH NOTECLICK HEREA CRUEL QUARTER FOR BONDSCLICK HERELMData093020","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL6N45M0NX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4588","XLK","BK4581","LABU","SOXQ","KRE","BK4535","XLB","BK4585","XBI","XLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671047562","title":"Health Care Select Sector SPDR: Pivot points","url":"https://stock-news.laohu8.com/highlight/detail?id=2671047562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671047562?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:37","pubTimestamp":1790771845,"startTime":"0","endTime":"0","summary":"The following are the pivot points for the Health Care Select Sector SPDR (XLV). Pivot High: $172.50, Pivot Low: $169.78. These were calculated usi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/health-care-select-sector-spdr-pivot-points-thefly-news-153?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/health-care-select-sector-spdr-pivot-points-thefly-news-153?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4585","BK4588","XBI","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671204888","title":"Abbott announces U.S. commercial launch of SimpleScreen CRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2671204888","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671204888?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:06","pubTimestamp":1790769961,"startTime":"0","endTime":"0","summary":"Abbott (ABT) announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbott-announces-u-s-commercial-launch-of-simplescreen-crc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbott-announces-u-s-commercial-launch-of-simplescreen-crc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","LU1057294990.SGD","SG9999002232.USD","LU1670627923.USD","IHI","SG9999004303.SGD","BK4588","LABU","LU1989763690.USD","LU0208291251.USD","LU0456854461.SGD","LU0114720955.EUR","BK4504","PJP","LU0882574055.USD","LU2324357040.USD","LU1989763427.SGD","BK4213","IE00BFTCPJ56.SGD","LU1721429402.USD","LU2112291526.USD","LU1670628061.USD","IE00BJT1NW94.SGD","LU0070302665.USD","LU2237957811.SGD","CRC","LU1023059063.AUD","SGXZ23171101.USD","LU2089984988.USD","LU0058720904.USD","LU2211815571.USD","LU0266013472.USD","LU1691799644.USD","BK4581","SG9999002224.SGD","TMED","LU0320765489.SGD","LU1721429741.USD","BK4082","LU2468319806.SGD","LU2133065610.SGD","LU0211331839.USD","IE0009355771.USD","LU0234572021.USD","IE00B2B36J28.USD","LU1914381329.SGD","LU0266512127.USD","BK4592","LU0432979614.USD","ABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671253201","title":"Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2671253201","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671253201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:00","pubTimestamp":1790769600,"startTime":"0","endTime":"0","summary":"REVTORPYK (gedatolisib)   REVTORPYK (gedatolisib) vial and box  REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371842/0/en/celcuity-announces-that-revtorpyk-gedatolisib-is-now-commercially-available-in-the-united-states.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRET","BK4599","BK4203","LU1878469433.USD","LABU","BK4585","UBCP","BK4211","NVIB","BK4225","IDNA","BK4139","ALT","BK4588","GDOC","HR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220950","title":"CeriBell Receives FDA Clearance for Platform Software Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220950","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220950?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:32","pubTimestamp":1790767962,"startTime":"0","endTime":"0","summary":"CeriBell (CBLL) has received the US Food and Drug Administration's approval for a software update that will add three capabilities to its namesake platform, the company said Wednesday.The new capabili","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","CBLL","BK4588","LABU","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671209180","title":"Tiziana Life Sciences Seeks FDA Orphan Status for Intranasal Foralumab in Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671209180","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671209180?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:28","pubTimestamp":1790767704,"startTime":"0","endTime":"0","summary":"An update from Tiziana Life Sciences ( ($TLSA) ) is now available. On September 30, 2026, Tiziana Life Sciences announced it has filed a request wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-seeks-fda-orphan-status-for-intranasal-foralumab-in-multiple-system-atrophy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-seeks-fda-orphan-status-for-intranasal-foralumab-in-multiple-system-atrophy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671209919","title":"Ceribell receives FDA 510k clearance of quantitative EEG trending, analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671209919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671209919?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:20","pubTimestamp":1790767236,"startTime":"0","endTime":"0","summary":"CeriBell (CBLL) announced that the U.S. Food and Drug Administration, FDA, has cleared new software for the Ceribell System that “makes it easier a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ceribell-receives-fda-510k-clearance-of-quantitative-eeg-trending-analysis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ceribell-receives-fda-510k-clearance-of-quantitative-eeg-trending-analysis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","VGT","BK4588","BK4082","QQH","LABU","CBLL","IGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671280201","title":"Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671280201","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671280201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371756/0/en/tiziana-life-sciences-files-for-orphan-drug-designation-with-the-fda-for-intranasal-foralumab-for-the-treatment-of-multiple-system-atrophy-msa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","LU2506951958.HKD","LU2247934214.USD","BK4183","LU2125909916.SGD","LABU","LU0823417653.USD","LU0053671581.USD","LU0823417737.USD","LU0154245756.USD","HERO","BK4085","LU1043141123.HKD","IE0009354923.USD","LU1430594728.SGD","LU1585245621.USD","LU2211815571.USD","LU2125909759.SGD","LU0640476718.USD","BK4533","BK4585","BK4532","BNGE","LU1923622291.USD","LU1280957306.USD","LU2506952097.USD","LU2506952170.USD","LU0728928796.USD","LU2506951875.HKD","LU0426417589.USD","LU0757428866.USD","LU1121112475.USD","LU0426412945.USD","ESPO","BK4577","LU0950375773.USD","EA","BK4588","LU0006061336.USD","BK4143","LU0994945656.USD","NERD","LU1043141396.HKD","LU1815336091.USD","MSA","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220149","title":"Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220149","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220149?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":"New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indicationsSUNNYVALE, Calif., Sept.  30, 2026 (GLOBE NEWSWI","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371750/0/en/ceribell-receives-fda-510-k-clearance-for-quantitative-eeg-trending-and-amplitude-integrated-eeg-analysis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMPL","LABU","BK4585","BK4588","CBLL","BK4023","RA","BK4082","SAH","BK4214"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205590","title":"Aldeyra Therapeutics: Neutral Rating Maintained Amid FDA Uncertainty; $2 Price Target Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205590?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:25","pubTimestamp":1790763928,"startTime":"0","endTime":"0","summary":"Analyst Matthew Caufield of H.C. Wainwright reiterated a Hold rating on Aldeyra Therapeutics, retaining the price target of $2.00. Matthew Caufield...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aldeyra-therapeutics-neutral-rating-maintained-amid-fda-uncertainty-2-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aldeyra-therapeutics-neutral-rating-maintained-amid-fda-uncertainty-2-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220846","title":"Roche’s Genentech announces FDA approves NDA for fenebrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220846","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220846?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:50","pubTimestamp":1790761812,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY) Group, announced that the U.S. FDA has accepted the company’s NDA under priority review for fenebrutinib, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roches-genentech-announces-fda-approves-nda-for-fenebrutinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roches-genentech-announces-fda-approves-nda-for-fenebrutinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","HRTS","RHHBY","BK4585","BK4007","BK4588","LABU","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671724342","title":"Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671724342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671724342?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:50","pubTimestamp":1790758222,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT), Tectonic Therapeutic (TEC...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbott-laboratories-abt-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbott-laboratories-abt-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE0002141913.USD","LU2112291526.USD","XBI","LU2468319806.SGD","LU1989763690.USD","LU0882574055.USD","BK4581","LU0128526141.USD","LU2089984988.USD","LU1061106388.HKD","SG9999004303.SGD","LU1670628061.USD","ABT","BK4585","SG9999002232.USD","BK4568","LU0868494617.USD","LU1023059063.AUD","LU0122379950.USD","LU0114720955.EUR","HCSG","TMED","IHI","XLV","LU1721429741.USD","LU0211331839.USD","LU1914381329.SGD","LU0170899867.USD","IE00B2B36J28.USD","LU2237957811.SGD","IE00BJJMRZ35.SGD","PJP","LU0289739699.SGD","LU1057294990.SGD","LU0320765489.SGD","LU1721429402.USD","TECX","LU0208291251.USD","LU2133065610.SGD","BK4139","LU0432979614.USD","SGXZ23171101.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","LABU","BK4137","LU0266013472.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671027487","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2671027487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671027487?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:20","pubTimestamp":1790756400,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0749 GMT - Fresenius investors might have overreacted to news th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOTE","LABU","BK4585","PMDE","BK4581","XBI","DECU","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671275727","title":"Yamashita Health Care Sees FY Net Y553.00m","url":"https://stock-news.laohu8.com/highlight/detail?id=2671275727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671275727?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:00","pubTimestamp":1790751600,"startTime":"0","endTime":"0","summary":"Yamashita Health Care Holdings Inc. also released the following forecasts:. Results are based on Japanese accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","LABU","BK4588","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122605627","title":"HUTCHMED Shares Rise Over 3% After Announcing FDA Submission for Orpathys and Tagrisso Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1122605627","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122605627?lang=en_us&edition=fundamental","pubTime":"2026-09-30 11:02","pubTimestamp":1790737370,"startTime":"0","endTime":"0","summary":"HUTCHMED (00013) shares rose more than 3%, reaching HK$23.04 as of press time, up 3.32%, with a turnover of HK$69.44 million.On September 29, HUTCHMED (00013) announced that AstraZeneca has submitted...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK4588","BK4585","BK1191","LABU","IPOS","VXUS","KCAI","BK1587","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221962","title":"IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671221962?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:11","pubTimestamp":1790734260,"startTime":"0","endTime":"0","summary":"0211 GMT - IHH Healthcare's recent share price weakness is likely an enhanced buying opportunity, with Fortis-related litigation concerns expected to have limited impact on operations, says Citi analyst Megat Fais in a note. IHH says it isn't subject to financial claims in the dispute involving Daiichi Sankyo and former Fortis promoters. IHH's India plans remain on track to reach 10,000 beds target by 2030-2031, while Singapore's recovery is expected to continue, he reckons. Malaysia should see growth from selective bed additions and medical tourism, while Turkey's strong demand and international patient flows are expected to continue, he adds. Citi keeps a buy rating and its target price at 10.40 ringgit. Shares are 0.1% higher at 7.88 ringgit.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","LU0029874061.USD","DSNKY","LU0128526141.USD","BK4007","BK4581","BK4588","HCSG","LABU","XLV","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":4,"totalSize":386,"code":"91000000","status":"200"}]}}